scholarly journals Extra ordinary high blood lead levels in Mashhad,Iran: a one-year study in a referral center

2021 ◽  
Vol 25 (2) ◽  
pp. 116-124
Author(s):  
Samaneh Boroumand-Noughabi ◽  
◽  
Mohammad Reza Keramati ◽  
Zahra Sadrzadeh Sadrzadeh, ◽  
Zohreh Asadi ◽  
...  
Keyword(s):  
Binding Capacity ◽  
Lead Toxicity ◽  
Blood Lead ◽  
Total Iron ◽  
Iron Binding ◽  
Total Iron Binding Capacity ◽  
Cell Counts ◽  
Blood Cell Counts ◽  
The Mean ◽  
Iron Binding Capacity

Introduction: Lead is a heavy metal with vast usage in the industry. Lead toxicity affects any organ in the body. It causes various clinical presentations, which leads to diagnostic complexity. Regarding recent increased observation of cases with lead toxicity in our center, we aimed to evaluate the frequencies of lead toxicity in patients referred to Imam-Reza Hospital’s laboratory and find a possible relationship between the blood lead level (BLL) and hematological and biochemical tests. Methods: From 2016 to 2017, the patients referred to Imam-Reza hospital’s laboratory to detect BLL enrolled in the study. Among them, 254 adult cases with BLLs≥10 μg/dl were selected. Complete blood counts and peripheral blood smear were done. Other lab data were extracted from hospital files. Results: The mean BLL of 1649 participants was 59.11±116.25 μg/dl, ranging from 0 to 1580. Sixty nine percent of them had lead toxicity. Eighty-one percent (n=1341) of patients were males and 18.7% (n=308) were females. In 254 selected cases, the mean BLL was 138.17±189.98 μg/dl. There were significant inverse correlations between BLL and red blood cell counts, hemoglobin, mean cell hemoglobin, total iron-binding capacity, target shape and basophilic stippling, as well as positive correlations between BLL and white blood cell counts, red cell distribution width, neutrophil counts and iron. Conclusion: Lead toxicity seems to be more frequent than it is expected. Patients with unexplained anemia with increased iron and decreased total iron-binding capacity are better to be evaluated for BLL.

scholarly journals The identification of ketotifen as a novel cardioprotective agent in patients undergoing anthracyclines chemotherapy

2021 ◽  
Author(s):  
hosny elewa ◽  
Naser elberay ◽  
Walaa Keshk ◽  
Hamada Abulkhair
Keyword(s):  
Breast Cancer ◽  
Binding Capacity ◽  
Serum Levels ◽  
Total Iron ◽  
Control Group ◽  
Controlled Clinical Trial ◽  
Iron Binding ◽  
Total Iron Binding Capacity ◽  
The Mean ◽  
Iron Binding Capacity

Objective: The present study aimed to investigate the possible cardioprotective effects of ketotifen and to assess its activity as an iron-chelating agent in patients receiving anthracyclines for the treatment of breast cancer. Patients & Methods: This was a randomized, prospective, controlled clinical trial. One hundred eleven eligible patients with breast cancer (age range, 30-60 years) were scheduled to receive anthracyclines chemotherapy. The patients were divided into two groups: Patients (n = 56) assigned to the ketotifen group received ketotifen 1 mg three times daily for six consecutive cycles of treatment, and patients assigned to the control group (n = 55) without ketotifen treatment. The echocardiogram for each patient was recorded two times at baseline and the end of the study. As well, blood samples were collected from all patients. Results: The findings showed a statistically significant reduction in the mean serum levels of common cardiotoxicity accompanied biomarkers in the ketotifen group compared with the control group (P ≤ 0.05). The mean serum levels of total iron-binding capacity were significantly elevated in the ketotifen group (P ≤ 0.001). There was a direct correlation between the mean serum levels of iron and that of lactate dehydrogenase (LDH) (r = + 0.79). On the other hand, there were indirect correlations between mean serum levels of LDH and both the percentage of ejection fraction and the total iron-binding capacity (r = - 0.69 and -0.697, respectively). Conclusion: Oral administration of ketotifen appears to be efficient and safe as a novel cardioprotective agent for the prevention of anthracyclines induced cardiotoxicity. Additionally, ketotifen suggested a beneficial effect in iron overload inducing diseases such as COVID-19.

scholarly journals Novel use of Ketotifen as a cardio-protective agent in patients undergoing anthracycline chemotherapy

2021 ◽  
Author(s):  
hosny elewa ◽  
Naser elberay ◽  
amany elsharif ◽  
Walaa Keshk ◽  
zeinab zalat
Keyword(s):  
Breast Cancer ◽  
Binding Capacity ◽  
Serum Levels ◽  
Total Iron ◽  
Control Group ◽  
Iron Binding ◽  
Total Iron Binding Capacity ◽  
The Mean ◽  
Iron Binding Capacity ◽  
Anthracycline Chemotherapy

Objective: The present study aimed to investigate the possible cardioprotective effects of ketotifen and to assess its activity as an iron-chelating agent in patients receiving anthracyclines for the treatment of breast cancer. Patients & Methods: This was a randomized, prospective, controlled clinical trial. 111 eligible patients with breast cancer (age range, 30-60 year) were scheduled to receive anthracycline chemotherapy. The patients divided into two groups: Patients (n=56) assigned to The ketotifen group received ketotifen 1 mg three times daily for six consecutive cycles of treatment, and patients assigned to The control group (n= 55) without ketotifen treatment. The echocardiogram for each patient was recorded two times at baseline and at the end of the study. As well, blood samples were collected from all patients. Results: The findings showed a statistically significant reduction in the mean serum levels of common cardiotoxicity accompanied biomarkers in The ketotifen group compared with The control group (P ≤ 0.05). The mean serum levels of total iron-binding capacity was significantly elevated in The ketotifen group (P ≤ 0.001). There was a direct correlation between the mean serum levels of iron and that of lactate dehydrogenase (LDH) (r = + 0.79). On the other hand, there were indirect correlations between mean serum levels of LDH and both the percentage of ejection fraction and the total iron-binding capacity (r = - 0.69 and -0.697, respectively). Conclusion: Oral administration of ketotifen appears to be efficient and safe as a novel cardioprotective agent for the prevention of anthracyclines induced cardiotoxicity. Additionally, ketotifen suggested a beneficial effect in iron overload inducing diseases such as COVID-19.

Serum Ferritin and Total Iron-Binding Capacity to Estimate Iron Storage in Pigs

1984 ◽  
Vol 21 (6) ◽  
pp. 597-600 ◽  
Author(s):  
J. E. Smith ◽  
K. Moore ◽  
D. Boyington ◽  
D. S. Pollmann ◽  
D. Schoneweis
Keyword(s):  
Serum Ferritin ◽  
Binding Capacity ◽  
Total Iron ◽  
Iron Binding ◽  
Total Iron Binding Capacity ◽  
Iron Storage ◽  
Iron Binding Capacity

Chemical and immunochemical measurement of total iron-binding capacity compared.

1978 ◽  
Vol 24 (10) ◽  
pp. 1788-1791 ◽  
Author(s):  
G J Buffone ◽  
S A Lewis ◽  
M Iosefsohn ◽  
J M Hicks
Keyword(s):  
Binding Capacity ◽  
Pediatric Population ◽  
Total Iron ◽  
The Other ◽  
Iron Binding ◽  
Total Iron Binding Capacity ◽  
Analytical Recovery ◽  
Immunochemical Methods ◽  
Iron Binding Capacity

Abstract Radiometric, colorimetric, and two immunochemical methods for measuring total iron-binding capacity are compared. We evaluated the procedures on the basis of precision, applicability to a pediatric population, and accuracy as assessed by analytical recovery of purified transferrin. The immunoephelometric assay for transferrin provides significant advantages over the other methods examined.

Sign in / Sign up

Export Citation Format

Share Document